Status:

COMPLETED

Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.

Lead Sponsor:

GlaxoSmithKline

Conditions:

Diphtheria

Hepatitis B

Eligibility:

All Genders

56-83 years

Phase:

PHASE3

Brief Summary

The purpose of the study is to demonstrate consistent results in 3 production lots of Hib-MenAC vaccine when extemporaneously mixed with Tritanrix™-HepB and administered as a single injection, with re...

Detailed Description

Randomized study with five groups to receive one of the following vaccination regimens after a birth dose of hepatitis B vaccine: One of the 3 lots of GSK Biologicals' Hib-MenAC mixed with GSK Biologi...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • • Healthy infants 56-83 days of age, written informed consent obtained from the parents, born after a gestation period of 36 to 42 weeks and received a birth dose of hepatitis B vaccine within the first 72 hours of life.
  • Exclusion criteria:
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history \& physical examination.
  • Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days before the first dose of study vaccine, or planned administration during the study period with the exception of oral polio vaccine (OPV).
  • Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (\>14 days) of immunosuppressants or other immune-modifying drugs since birth.
  • Bacille Calmette-Guérin (BCG) vaccine received after the first 2 weeks of life.
  • Previous vaccination against diphtheria, tetanus, pertussis, Haemophilus influenzae type b, and/or meningococcal disease.

Exclusion

    Key Trial Info

    Start Date :

    August 1 2004

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 1 2005

    Estimated Enrollment :

    1000 Patients enrolled

    Trial Details

    Trial ID

    NCT00317161

    Start Date

    August 1 2004

    End Date

    April 1 2005

    Last Update

    September 20 2016

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    GSK Investigational Site

    Bangkok, Thailand, 10400

    2

    GSK Investigational Site

    Khon Kaen, Thailand, 40002

    3

    GSK Investigational Site

    Songkhla, Thailand, 90110